

REMARKS Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/844,450
				Filing Date	April 27, 2001
				First Named Inventor	Frey II, William H.
				Art Unit	1623
				Examiner Name	Mcintosh III, Travis
				Attorney Docket Number	83935

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

[illegible][illegible]

Examiner Signature		Date Considered	8/1/04
-----------------------	---	--------------------	--------

Date
Considered


8/1/04

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTP/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/844,450
			Filing Date	April 27, 2001
			First Named Inventor	Frey II, William H.
			Group Art Unit	1623
			Examiner Name	Mcintosh III, Travis
			Attorney Docket Number	83935
Sheet	2	of	2	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
(A)	C	FAWCETT, John R. et al.; "Brain Research 850 (2002) 10-20: Research Report: Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants"; Elsevier Science B.V.; www.elsevier.com/locate/bres; US 2002.	
(B)	D	KORNBERG, Arthur, et al.; "Inorganic Polyphosphate: A Molecule of Many Functions"; Annual Review Biochemistry, Vol 68: 89 – 125; Annual Reviews; US 1999.	
(C)	E	FREY II, William H. et al.; "Brain Research 714 (1996) 87 - 94: Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor"; Elsevier Science B.V.; US 1996.	
(D)	F	FREY II, William H. et al.; "Brain Research 655 (1994) 153 - 180: Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain"; Elsevier Science B.V.; US 1994.	
	G	HOMER JR, Homer D. et al.; "Brain Research 764 (1997) 93 - 100: Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation"; Elsevier Science B.V.; US 1997.	
	H	BORDAYO, Elizabeth et al.; "Bilirubin, Myricetin and Carnosol Protect the Human Brain Muscarinic Acetylcholine Receptor from Free Radical Damage"; Alzheimer's Research Center; US – unknown.	
	I	FAWCETT, John R. et al.; "The Human Brain Muscarinic Acetylcholine Receptor is Inactivated by Free Radicals Produced by a Low Molecular Weight Endogenous Inhibitor from Alzheimer's Brain"; Alzheimer's Research Center; US – unknown.	
(E)	J	OTTERBEIN, Leo E. et al.; "Invited Review: Heme oxygenase: colors of defense against cellular stress"; The American Physiological Society; www.ajplung.org; US 2000.	

Duplicate
Reference
No Date
No Date

Examiner Signature		Date Considered	8/1/2004
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patents, Washington, DC 20231.